Skip to the page

Data / Drug companies / Wilshire Pharmaceuticals, Inc.

Wilshire Pharmaceuticals, Inc.: 48 products in the FDA NDC directory, labeler code 52536

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Wilshire Pharmaceuticals, Inc. (labeler code 52536) lists 48 products in the FDA National Drug Code Directory, covering 16 finished drugs by generic name. By type: 48 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 27, 2026.

The request: Watch Wilshire Pharmaceuticals, Inc. (FDA labeler code 52536): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
52536
Products in commercial distribution
48
Packages
57
Finished drugs by generic name
16
Prescription products
48
Over the counter products
0
Controlled substance products
Schedule II 7, Schedule III 1, Schedule IV 2
Flagged as original packager
46 of 46 products that carry the flag
Started marketing in the last 12 months
8
Products with a marketing end date set
2
Earliest marketing start
May 29, 1990
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)2143.8%
Authorized generics (NDA)1531.2%
New drug applications (NDA)1225%

Products by type

TypeProductsShare
Prescription drugs48100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet1122.9%
Tablet, film coated714.6%
Kit48.3%
Capsule, delayed release48.3%
Tablet, delayed release36.2%
Suspension36.2%
Injection36.2%
Capsule, extended release36.2%
Capsule, gelatin coated36.2%
Powder, for solution24.2%
Solution, concentrate24.2%
Granule, for suspension24.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Azilsartan Medoxomil52536-008TabletNew drug applications (NDA)April 27, 2026
Azilsartan Medoxomil52536-004TabletNew drug applications (NDA)April 27, 2026
Lomustine52536-342Capsule, gelatin coatedNew drug applications (NDA)April 15, 2026
Lomustine52536-341Capsule, gelatin coatedNew drug applications (NDA)April 15, 2026
Lomustine52536-340Capsule, gelatin coatedNew drug applications (NDA)April 15, 2026
PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride52536-302Powder, for solutionAuthorized generics (NDA)April 15, 2026
Sodium sulfate, potassium sulfate and magnesium sulfate52536-177Solution, concentrateNew drug applications (NDA)April 15, 2026
Sodium sulfate, potassium sulfate and magnesium sulfate52536-175Solution, concentrateNew drug applications (NDA)April 15, 2026
Dexmedetomidine hydrochloride52536-126InjectionGeneric drugs (ANDA)January 30, 2025
Dexmedetomidine hydrochloride52536-125InjectionGeneric drugs (ANDA)January 30, 2025
Verapamil Hydrochloride52536-487Capsule, extended releaseAuthorized generics (NDA)November 26, 2024
Verapamil Hydrochloride52536-486Capsule, extended releaseAuthorized generics (NDA)November 26, 2024
Verapamil Hydrochloride52536-485Capsule, extended releaseAuthorized generics (NDA)November 26, 2024
Enalapril maleate52536-401SolutionNew drug applications (NDA)April 8, 2024
Baclofen52536-600SuspensionAuthorized generics (NDA)April 1, 2023
Vancomycin Hydrochloride for Oral Solution52536-108KitAuthorized generics (NDA)March 31, 2023
Vancomycin Hydrochloride for Oral Solution52536-107KitAuthorized generics (NDA)March 31, 2023
Vancomycin Hydrochloride for Oral Solution52536-106KitAuthorized generics (NDA)March 31, 2023
Vancomycin Hydrochloride for Oral Solution52536-104KitAuthorized generics (NDA)March 31, 2023
Isosorbide dinitrate and hydralazine hydrochloride52536-006Tablet, film coatedAuthorized generics (NDA)April 15, 2022
Dextroamphetamine Sulfate52536-530TabletGeneric drugs (ANDA)August 6, 2021
Dextroamphetamine Sulfate52536-520TabletGeneric drugs (ANDA)August 6, 2021
Dextroamphetamine Sulfate52536-515TabletGeneric drugs (ANDA)August 6, 2021
Erythromycin ethylsuccinate52536-132SuspensionNew drug applications (NDA)August 24, 2020
Erythromycin52536-186Tablet, delayed releaseGeneric drugs (ANDA)July 22, 2019

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.